Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594658 | 0.76 | ALDH1A1 (0.45) | ALDH1A1CYP2A6IDH1EGLN2AR | |
| SCHEMBL9276544 | 0.71 | ALOX15 (0.44) | ALDH1A1PDE10A | |
| SCHEMBL4804053 | 0.68 | ACHE (0.41) | ALDH1A1CYP2A6MEN1NPC1MAPT | |
| SCHEMBL10053617 | 0.68 | PDE10A (0.45) | ALDH1A1NPC1RAB9ASMN1; SMN2PDE10A | |
| SCHEMBL24423211 | 0.67 | TBXAS1 (0.40) | — | |
| SCHEMBL4636296 | 0.67 | GRM5 (0.42) | ALDH1A1MEN1NPC1MAPTRAB9A | |
| SCHEMBL7169879 | 0.67 | MEN1 (0.36) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL321553 | 0.66 | ALOX15 (0.48) | ALDH1A1MEN1NPC1MAPTRAB9A | |
| SCHEMBL10123586 | 0.66 | TSHR (0.35) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1994209 | 0.65 | ALDH1A1 (0.43) | ALDH1A1MEN1NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| CN-101678009-A | Indolizine acetic acid derivatives as CRTH2 antagonists | ARGENTA DISCOVERY LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009044134-A1 | INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| CN-101305001-A | Indolizine derivatives as ligands of the CRTH2 receptor | ARGENTA DISCOVERY LTD (GB) | 2008-11-12 | — | — | CN | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | ALDH1A1 3463/4885CYP2A6 352/4885MEN1 3938/4885 |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | HRH1, HRH4, HRH2 | ALDH1A1 744/4885CYP2A6 2841/4885MEN1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.